News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

New Contract Signals Strong Year of Sales for Allied


11/7/2012 9:54:26 AM

Brisbane, Australia, 7th November 2012 -- Australian biomedical company Allied Healthcare Group (ASX: AHZ) has secured a five year contract to supply an infusion management platform to a North Queensland hospital.

Allied will supply the Swiss-made Arcomed infusion management system after Mater Health Service North Queensland (MHSNQ), awarded the company the contract.

Lee Rodne, Group Managing Director, Allied Healthcare Group said the contract was the latest in a period of strong sales growth and it validated efforts to bring the technology to Australia.

“This robust and cutting-edge device represents the latest in infusion management technology, which is designed to improve both hospital efficiency and clinical outcomes for patients by using data management to ensure patients receive the correct medication at the correct time” Mr Rodne said.

“This five year supply contract also signals a growing recognition of Allied as a leading provider of innovative medical products and technologies, to Australian and New Zealand hospitals and healthcare facilities.”

Allied Healthcare Group has the sole license to distribute Arcomed’s technology platform in Australia. MHSNQ is the first facility to introduce the infusion platform since it became available in Australia earlier this year.

Allied’s sales and marketing division are also preparing for the launch of its lead regenerative tissue product CardioCel®. Allied will leverage off its experience and infrastructure to sell CardioCel® into a number of countries, including Australia and New Zealand once it is approved. Allied anticipates the global launch of CardioCel® to significantly increase revenue for the company once approved.

Sales revenue of up to $2 million is expected across the life of the contract. Allied currently generates around $7 million in sales annually from an extensive range of unique cardiology and infusion products.

Mr Rodne said sales revenue in the last quarter was 25% up from the corresponding period in 2011.

“Allied has a strong specialist sales team that has a presence across all states of Australia and in New Zealand,” Mr Rodne said.

“Allied is expecting strong growth from its existing product range and we plan to introduce a string of new technologies that will further expand revenue from the Sales and Marketing

Division in coming years as we bring new products to market.”

For more information, please contact:

Dr Julian Chick, Chief Operating Officer Allied Healthcare Group Tel: +61 3 9620 5454

Media: Shevaun Cooper Buchan Consulting +61 3 9866 4722 scooper@buchanwe.com.au

About Allied Healthcare Group Limited

Allied Healthcare Group Limited (ASX: AHZ) is a diversified healthcare company focused on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow its product and service offerings and expanding revenues from its existing profitable medical Sales and Marketing division. The Company has assets from research & development, clinical development as well as sales and marketing of medical devices and technologies.

Allied Healthcare Group is in the process of commercialising its innovative tissue engineering technology for regenerative medicine. Allied also has major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programs target disease with significant global potential like herpes and Human Papilloma Virus.


Read at BioSpace.com

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES